Author

Robert O. Kerr

Observed names: R O Kerr, R. Kerr, R. O. Kerr, R.O. Kerr, Robert Kerr, Robert O Kerr

Observed institutions: Roswell Park Comprehensive Cancer Center, University of Minnesota, Hackensack University Medical Center, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, The University of Texas at San Antonio Health Science Center, Vanderbilt University, Loma Linda University, Louisiana State University in Shreveport, Henry Ford Hospital, University of Chicago, United States Air Force, Dana-Farber Cancer Institute, Minneapolis VA Medical Center, AstraZeneca (United States), Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University Health Sciences, Wake Forest University

OpenAlex ID: A5034887576

The Impact of Age on Delivered Dose Intensity and Hospitalizations for Febrile Neutropenia in Patients with Intermediate-Grade Non-Hodgkin's Lymphoma Receiving Initial CHOP Chemotherapy: A Risk Factor Analysis

2001 · Vicki A. Morrison, Vincent Picozzi, et al. · Clinical Lymphoma · 144

High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

2009 · Jorge E. Cortes, Hagop M. Kantarjian, et al. · Journal of Clinical Oncology · 125

Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer

2009 · Muhammad Saif, Nikolai Podoltsev, et al. · Cancer Investigation · 91

Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain

1997 · Alan Broomhead, Robert Kerr, et al. · Journal of Pain and Symptom Management · 83

PDF

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

2009 · Raman Sood, Harry Carloss, et al. · American Journal of Hematology · 49

PDF

Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC

2005 · B. E. Johnson, P. Ma, et al. · Journal of Clinical Oncology · 42

Two Mechanisms of Erythrocyte Destruction in Penicillin-Induced Hemolytic Anemia

1972 · Robert O. Kerr, Joseph Cardamone, et al. · New England Journal of Medicine · 38

Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.

2001 · V J Picozzi, B L Pohlman, et al. · PubMed · 35

Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study

2008 · M. P. Jhawer, H. L. Kindler, et al. · Journal of Clinical Oncology · 23

Erythrocyte-Bound C5 and C6 in Autoimmune Hemolytic Anemia

1971 · Robert O Kerr, Agustin P Dalmasso, et al. · The Journal of Immunology · 17

A Patient Preference Study Comparing Two Extended-Release Morphine Sulfate Formulations (Once-Daily Kadian?? versus Twice-Daily MS Contin??) for Cancer Pain

2000 · Robert O. Kerr, William J. Tester · Clinical Drug Investigation · 16

P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study

2005 · J. Hevmach, H. West, et al. · Lung Cancer · 14

Phase II clinical trial of paclitaxel loaded polymeric micelle (GPM) in patients (pts) with advanced pancreatic cancer (APC): Final results

2008 · N. A. Podoltsev, M. S. Rubin, et al. · Journal of Clinical Oncology · 9

A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

2005 · M. Lilly, P. Kuriakose, et al. · Journal of Clinical Oncology · 5

A Phase II Study of Denileukin Diftitox (ONTAKR) in Patients with Fludarabine Refractory B-Cell Chronic Lymphocytic Leukemia.

2004 · Philip Kuriakose, Francesco Turturro, et al. · Blood · 5

A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients

1978 · Arthur H. Rossof, Robert O. Kerr, et al. · Medical and Pediatric Oncology · 4

873 KadianTM/kapanolTM—A once daily morphine formulation

1995 · A.F. Broomhead, R.O. Kerr, et al. · European Journal of Cancer · 2

Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: an interim safety analysis

2008 · A.D. Seidman, A.K. Conlin, et al. · European Journal of Cancer Supplements · 1

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

2004 · Jonathan Friedberg, Philip Cohen, et al. · Blood · 1

Relationship of effective titrated dose of fentanyl pectin nasal spray to background opioid dose in breakthrough pain in cancer.

2011 · S. M. Weinstein, R. O. Kerr, et al. · Journal of Clinical Oncology

Paroxysmal Nocturnal Hemoglobinuria: The Significance of Iron Deficiency, Pancytopenia, and Cyclic Neutropenia Case Report

1978 · Gerald M. Koppes, Robert O. Kerr · Military Medicine

Carbamyl phosphate mediated inhibition of the sickling of erythrocytes in whole blood in vitro from sickle cell anemia patients.

1971 · R O Kerr, A P Dalmasso, et al. · PubMed

Works count: 22

Citation count: 704

H-index: 12

I10-index: 12